Implandata Ophthalmic Products GmbH, a Hanover, Germany-based developer of an innovative diagnosis tool for glaucoma therapy, has raised €1.4m in Series A financing.
Backers include Hannover Beteiligungsfonds, High-Tech Gründerfonds and a group of private investors.
Led by co-founder and Managing Director Max G. Ostermeier, Implandata Ophthalmic Products GmbH has developed a system that makes it possible to continuously measure the intraocular pressure of glaucoma patients. It consists of a minimally invasive micro-sensor and a hand-held unit. The company has already begun the CE approval process, carried out the first implantations and expects market entry in the next 12 to 18 months.
Implandata Ophthalmic Products said it is in an advanced stage talks with possible investors for a second closing round, which should be completed by the end of March 2012.